Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 258

Sort by

Sort Order Select

Journal Articles

Monitoring of CNS involvement in AML using ultrahigh-sensitivity next-generation sequencing of cell-free DNA

Blood (2025) 146 (Supplement 1): 3515.

https://doi.org/10.1182/blood-2025-3515

Published: 2025

Journal Articles

Umbilical cord blood CD34+ hematopoietic stem cell-derived natural killer cells in Acute Myeloid Leukemia – a phase I clinical study

Blood (2025) 146 (Supplement 1): 1640.

https://doi.org/10.1182/blood-2025-1640

Published: 2025

Journal Articles

CYP3A4 inhibitors (CYP3A4i) and myelosuppression in patients (Pts) with newly diagnosed mutant isocitrate dehydrogenase 1 (mIDH1) Acute Myeloid Leukemia (AML) in the phase 3 AGILE study

Andre Schuh, Pau Montesinos, Christian Recher, Michael Heuser, Susana Vives, Ewa Zarzycka, Marta Riva, Rodrigo Calado, Su-Peng Yeh, Courtney DiNardo, Mohammad Hossain, Jianan Hui, Diego Gianolio, Assaf Vestin, Rui Ding, Prapti Patel, Stéphane De Botton, Hartmut Döhner, Jianxiang Wang

Blood (2025) 146 (Supplement 1): 3440.

https://doi.org/10.1182/blood-2025-3440

Published: 2025

Journal Articles

Establishing contemporary benchmarks for Acute Myeloid Leukemia outcomes and measurable residual disease: Real-world data utilization from the ELN-david MRD international working group

Blood (2025) 146 (Supplement 1): 5183.

https://doi.org/10.1182/blood-2025-5183

Published: 2025

Journal Articles

Deep learning-based histopathological subtyping of peripheral T-cell lymphoma (PTCL) on H&E-stained whole slide images

Sarah Bernhardt, Leonie Oevel, Hilka Rauert-Wunderlich, Filip Kramarzyk, Elisabeth Groß, Franziska Schümann, Edith Willscher, Marcus Bauer, Claudia Wickenhauser, Michael Heuser, Andreas Rosenwald, Jakob Kather, Chiara Löffler, Thomas Weber

Blood (2025) 146 (Supplement 1): 1784.

https://doi.org/10.1182/blood-2025-1784

Published: 2025

Journal Articles

The simplified age and stage (SAS) score improves OS prediction after allogeneic stem cell transplantation

Alexander Angleitner, Markus Maulhardt, Michael Heuser, Judith Büntzel, Wolfram Jung, Justin Hasenkamp, Gerald Wulf

Blood (2025) 146 (Supplement 1): 7815.

https://doi.org/10.1182/blood-2025-7815

Published: 2025

Journal Articles

Clinical characteristics and comutational landscape of CSF3R mutations in acute myeloid leukemia

Lara Wiechers, Rabea Mecklenbrauck, Razif Gabdoulline, Henri C. Hupe, Piroska Poll, Rabia Shahswar, Franziska Westendorf, Walter Fiedler, Arnold Ganser, Florian Heidel, Michael Heuser, Felicitas R Thol

Blood (2025) 146 (Supplement 1): 1718.

https://doi.org/10.1182/blood-2025-1718

Published: 2025

Journal Articles

Matched unrelated vs. Haploidentical donor for allogeneic stem cell transplantation in patients with acute leukemia with identical GvHD prophylaxis – a randomized prospective european trial.

Blood (2025) 146 (Supplement 1): 171.

https://doi.org/10.1182/blood-2025-171

Published: 2025

Journal Articles

Prognostic risk integration for survival modeling (PRISM) in newly diagnosed acute myeloid leukemia treated with venetoclax: a multinational retrospective cohort study

Blood (2025) 146 (Supplement 1): 453.

https://doi.org/10.1182/blood-2025-453

Published: 2025

Journal Articles

Independent, international validation of the unsupervised harmony classification of Acute Myeloid Leukemia

Blood (2025) 146 (Supplement 1): 451.

https://doi.org/10.1182/blood-2025-451

Published: 2025

Journal Articles

Outcomes following lower-intensity therapy with venetoclax in patients with NPM1-mutated Acute Myeloid Leukemia are highly dependent upon co-occurring mutations

Blood (2025) 146 (Supplement 1): 5278.

https://doi.org/10.1182/blood-2025-5278

Published: 2025

Journal Articles

Adding eltrombopag to immunosuppressive treatment with cyclosporine as front-line therapy for moderate aplastic anemia improves trilineage hematologic response: One-year analysis of the randomised, placebo-controlled, double-blind Phase III trial eltrombopag for moderate aplastic anemia (EMAA Trial)

Britta Hoechsmann, Philippe Schafhausen, Fabian Beier, Michael Heuser, Joerg Westermann, Beatrice Drexler, Alexander Röth, Mathias Hänel, Flore Sicre-de-Fontbrune, Astrid Marx-Hofmann, Antonia Beitzen-Heineke, Jens Panse, Felicitas R Thol, Sixten Koerper, Tim H. Brummendorf, Hubert Schrezenmeier

Blood (2025) 146 (Supplement 1): 980.

https://doi.org/10.1182/blood-2025-980

Published: 2025

Journal Articles

Risk factor analysis of relapse risk during FLT3-inhibitor post-transplant maintenance therapy following allogeneic hematopoietic stem cell transplantation in Acute Myeloid Leukemia with FLT3-ITD

Blood (2025) 146 (Supplement 1): 4284.

https://doi.org/10.1182/blood-2025-4284

Published: 2025

Journal Articles

Validation of measurable residual disease as a surrogate endpoint in acute myeloid leukemia: A HARMONY Alliance study of European randomized trials

Blood (2025) 146 (Supplement 1): 343.

https://doi.org/10.1182/blood-2025-343

Published: 2025

Journal Articles

Unleashing intrinsic inflammation in AML using therapeutic cytokines overcomes pro-survival pathways and induces deep and durable remission In Vivo.

Blood (2025) 146 (Supplement 1): 3280.

https://doi.org/10.1182/blood-2025-3280

Published: 2025

Journal Articles

Intra-Tumor Heterogeneity in Core-Binding Factor Acute Myeloid Leukemia

Raphael Hablesreiter, Paulina Strzelecka, Natalia Estrada, Klara Kopp, Anna Dolnik, Marlon Tilgner, Coral Fustero, Felicitas R Thol, Florian H. Heidel, Michael Heuser, Lars Bullinger, Friederike Christen, Frederik Damm

Blood (2024) 144 (Supplement 1): 2956.

https://doi.org/10.1182/blood-2024-202342

Published: 2024

Journal Articles

Prognostic Role of NGS-Based MRD Assessment in FLT3 -TKD Mutated Patients with Acute Myeloid Leukemia

Isabell Arnhardt, Christian M. Vonk, Xavier Cheng-Hong Tsai, Felicitas R. Thol, Wen-Chien Chou, Hsin-An Hou, Razif Gabdoulline, Florian H. Heidel, Hwei-Fang Tien, Michael Heuser, Peter J. M. Valk

Blood (2024) 144 (Supplement 1): 2951.

https://doi.org/10.1182/blood-2024-207981

Published: 2024

Journal Articles

A Venetoclax/Azacytidine Single-Cell RNA-Seq Resistance Signature (VARS) Predicts Response and Relapse in AML Patients

Anne Kathrin Merbach, Christian Rohde, Sergi Beneyto-Calabuig, Patrick Stelmach, Aino-Maija Leppä, Alexander Waclawiczek, Simon Renders, Michelle Lotze, Lars Velten, Andreas Trumpp, Tim Sauer, Rabia Shahswar, Michael Heuser, Carsten Müller-Tidow, Maike Janssen

Blood (2024) 144 (Supplement 1): 5744.

https://doi.org/10.1182/blood-2024-209706

Published: 2024

Journal Articles

Prognostic Impact of Subclinical FLT3 -ITD Microclones in Patients with Acute Myeloid Leukemia

Paul Olson, Razif Gabdoulline, Rabia Shahswar, Arnold Kloos, Letizia Venturini, Isabell Arnhardt, Henri C. Hupe, Victoria Panagiota, Michael Stadler, Matthias Eder, Gernot Beutel, Elke Dammann, Piroska Poll, Anke Bergmann, Nataliya DiDonato, Florian H. Heidel, Felicitas R. Thol, Michael Heuser

Blood (2024) 144 (Supplement 1): 847.

https://doi.org/10.1182/blood-2024-207703

Published: 2024

Journal Articles

The Prognostic Impact of Myelodysplasia-Related Gene Mutations in Acute Myeloid Leukemia with FLT3 -ITD Mutations

Blood (2024) 144 (Supplement 1): 844.

https://doi.org/10.1182/blood-2024-202362

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Monitoring of CNS involvement in AML using ultrahigh-sensitivity next-generation sequencing of cell-free DNA

Umbilical cord blood CD34+ hematopoietic stem cell-derived natural killer cells in Acute Myeloid Leukemia – a phase I clinical study

CYP3A4 inhibitors (CYP3A4i) and myelosuppression in patients (Pts) with newly diagnosed mutant isocitrate dehydrogenase 1 (mIDH1) Acute Myeloid Leukemia (AML) in the phase 3 AGILE study

Establishing contemporary benchmarks for Acute Myeloid Leukemia outcomes and measurable residual disease: Real-world data utilization from the ELN-david MRD international working group

Deep learning-based histopathological subtyping of peripheral T-cell lymphoma (PTCL) on H&E-stained whole slide images

The simplified age and stage (SAS) score improves OS prediction after allogeneic stem cell transplantation

Clinical characteristics and comutational landscape of CSF3R mutations in acute myeloid leukemia

Matched unrelated vs. Haploidentical donor for allogeneic stem cell transplantation in patients with acute leukemia with identical GvHD prophylaxis – a randomized prospective european trial.

Prognostic risk integration for survival modeling (PRISM) in newly diagnosed acute myeloid leukemia treated with venetoclax: a multinational retrospective cohort study

Independent, international validation of the unsupervised harmony classification of Acute Myeloid Leukemia

Outcomes following lower-intensity therapy with venetoclax in patients with NPM1-mutated Acute Myeloid Leukemia are highly dependent upon co-occurring mutations

Adding eltrombopag to immunosuppressive treatment with cyclosporine as front-line therapy for moderate aplastic anemia improves trilineage hematologic response: One-year analysis of the randomised, placebo-controlled, double-blind Phase III trial eltrombopag for moderate aplastic anemia (EMAA Trial)

Risk factor analysis of relapse risk during FLT3-inhibitor post-transplant maintenance therapy following allogeneic hematopoietic stem cell transplantation in Acute Myeloid Leukemia with FLT3-ITD

Validation of measurable residual disease as a surrogate endpoint in acute myeloid leukemia: A HARMONY Alliance study of European randomized trials

Unleashing intrinsic inflammation in AML using therapeutic cytokines overcomes pro-survival pathways and induces deep and durable remission In Vivo.

Intra-Tumor Heterogeneity in Core-Binding Factor Acute Myeloid Leukemia

Prognostic Role of NGS-Based MRD Assessment in FLT3 -TKD Mutated Patients with Acute Myeloid Leukemia

A Venetoclax/Azacytidine Single-Cell RNA-Seq Resistance Signature (VARS) Predicts Response and Relapse in AML Patients

Prognostic Impact of Subclinical FLT3 -ITD Microclones in Patients with Acute Myeloid Leukemia

The Prognostic Impact of Myelodysplasia-Related Gene Mutations in Acute Myeloid Leukemia with FLT3 -ITD Mutations

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only